MyFinsight
Home
Blog
About
Cash and cash
equivalents
$336,477K
(209.73%↑ Y/Y)
Short-term investments
$211,383K
(-39.01%↓ Y/Y)
Accounts receivable, net
$45,067K
(131.66%↑ Y/Y)
Inventory
$33,164K
(87.41%↑ Y/Y)
Collaboration receivable, net
$22,359K
(81.54%↑ Y/Y)
Prepaid expenses and
other current assets
$17,480K
(77.01%↑ Y/Y)
Short-term deposits
$6,406K
(-52.45%↓ Y/Y)
Other receivable, net
$2,703K
(-25.52%↓ Y/Y)
Property and equipment,
gross
$646K
Total current assets
$675,039K
(26.96%↑ Y/Y)
Long-term investments
$27,217K
(-56.54%↓ Y/Y)
Right-of-use asset, net
$1,082K
(-33.58%↓ Y/Y)
Property and equipment,
net
$212K
Restricted cash
$102K
(-53.00%↓ Y/Y)
Accumulated depreciation
$434K
Total assets
$703,652K
(18.03%↑ Y/Y)
Total liabilities and
stockholders equity
$703,652K
(18.03%↑ Y/Y)
Total liabilities
$688,553K
(56.94%↑ Y/Y)
Total stockholders
equity
$15,099K
(-90.41%↓ Y/Y)
Accumulated deficit
-$1,598,616K
(-16.02%↓ Y/Y)
Accumulated other
comprehensive (loss) gain
-$140K
(-149.12%↓ Y/Y)
Total long-term
liabilities
$588,876K
(80.78%↑ Y/Y)
Total current
liabilities
$99,677K
(-11.78%↓ Y/Y)
Additional paid-in capital
$1,613,846K
(5.14%↑ Y/Y)
Common stock, 0.0001
par value,...
$9K
(0.00%↑ Y/Y)
Royalty interest
financing liability, less...
$344,026K
(6.05%↑ Y/Y)
Convertible note liability
$244,090K
Right-of-use liability, less
current portion
$760K
(-42.64%↓ Y/Y)
Accrued expenses and
other current...
$94,297K
(32.69%↑ Y/Y)
Accounts payable
$4,874K
(-71.91%↓ Y/Y)
Current portion of
right-of-use liability
$506K
(47.09%↑ Y/Y)
Back
Back
Balance Sheet
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)
source: myfinsight.com